Research output per year
Research output per year
Personal profile
Biography
2010 - present
Academic staff, currently Reader, University of Manchester, Faculty of Life Sciences and then Faculty of Biology, Medicine and Health
2004 - 2010
Cancer Research UK Career Development Fellow, University of Manchester
1999-2004
Post-doctoral research associate with Hans Clevers, Academic Hospital Utrecht and Hubrecht Laboratories, The Netherlands
1998
PhD University of Glasgow, Faculty of Medicine. Research performed at Beatson laboratories under the supervison of Dr Donald M. Black
Research interests
Currently, my laboratory investigates how to harness T cells to eradicate cancer. On the one hand, we investigate adaptive resistance to immune checkpoint inhibitors, a class of drugs that reinvigorate T cells that have become dysfunctional in cancers. Sometimes this dysfunction appears in response to therapy (adaptive resistance) and our aim is to reverse this in order to preserve a clinical response. We are also engineering naive T cells to react to tumour antigens by providing them with novel antigen receptors. Again these engineered T cells may become inactive after being inside the tumour microenvironment and we are investigating how to overcome this obstacle too.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Doctor of Philosophy, The Beatson Institute for Cancer Research
Oct 1994 → Sept 1998
Award Date: 14 Aug 1998
Bachelor of Arts, Natural Sciences, University of Cambridge
Oct 1990 → Jun 1994
Award Date: 30 Jun 1994
Research Beacons, Institutes and Platforms
- Lydia Becker Institute
Fingerprint
Dive into the research topics where Adam Hurlstone is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Combined PARP14 Inhibition and PD-1 Blockade Promotes Cytotoxic T Cell Quiescence and Modulates Macrophage Polarization in Relapsed Melanoma
Lesham, R., Sefton, K. N., Wong, C. W., Lin, I.-H., Isaac, D. T., Niepel, M. & Hurlstone, A. F. L., 9 Jan 2025, (Accepted/In press) In: Journal for ImmunoTherapy of Cancer.Research output: Contribution to journal › Article › peer-review
-
A trafficking regulatory subnetwork governs α Vβ 6 integrin-HER2 cross-talk to control breast cancer invasion and drug resistance.
Maldonado, H., Dreger, M., Bedgood, L. D., Kyriakou, T., Wolanska, K. I., Rigby, M. E., Marotta, V. E., Webster, J. M., Wang, J., Rusilowicz-Jones, E. V., Marshall, J. F., Coulson, J. M., Macpherson, I. R., Hurlstone, A. & Morgan, M. R., 6 Dec 2024, In: Science Advances. 10, 49, p. eadk9944Research output: Contribution to journal › Article › peer-review
-
Abstract 625: PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven adaptive resistance
Wong, C. W., Evangelou, C., Sefton, K. N., Leshem, R., Sergiou, K., Carro, M. L. F., Uzuner, E., Mole, H., Telfer, B. A., Wilcock, D. J., Smith, M. P., Kunii, K., Perl, N. R., Lorigan, P., Williams, K. J., Rao, P. E., Nagaraju, R. T., Niepel, M. & Hurlstone, A. F., 1 Apr 2023. 1 p.Research output: Contribution to conference › Abstract › peer-review
-
A TIAM1-TRIM28 complex mediates epigenetic silencing of protocadherins to promote migration of lung cancer cells
Ginn, L., Maltas, J., Baker, M., Chaturvedi, A., Wilson, L., Guilbert, R., Amaral, F. M. R., Priest, L., Mole, H., Blackhall, F., Diamantopoulou, Z., Somervaille, T., Hurlstone, A. & Malliri, A., 3 Oct 2023, In: Proceedings of the National Academy of Sciences. 120, 40, e2300489120.Research output: Contribution to journal › Article › peer-review
Open Access -
PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models
Wong, C. W., Evangelou, C., Sefton, K. N., Leshem, R., Zhang, W., Gopalan, V., Chattrakarn, S., Fernandez Carro, M. L., Uzuner, E., Mole, H., Wilcock, D. J., Smith, M. P., Sergiou, K., Telfer, B. A., Isaac, D. T., Liu, C., Perl, N. R., Marie, K., Lorigan, P. & Williams, K. J. & 4 others, , 26 Sept 2023, In: Nature Communications. 14, 1, 5983.Research output: Contribution to journal › Article › peer-review
Open Access
Projects
- 10 Finished
-
DGAT1 is a Novel Melanoma Oncogene.
Hurlstone, A. (PI), Lorigan, P. (CoI) & Nicolaou, A. (CoI)
1/06/19 → 31/05/20
Project: Research
-
-
Targeting the inflammatory microenvironment in melanoma
Hurlstone, A. (PI)
1/09/15 → 30/06/19
Project: Research
-
Characterising T helper subsets in the model teleost zebrafish (Danio rerio) - JOINT APPLICATION WITH UNIVERSITY OF ABERDEEN
Hurlstone, A. (PI)
1/03/14 → 28/02/17
Project: Research
-
Can the immune response to melanoma be engineered through reprogramming CD4 helper cells.
Hurlstone, A. (PI)
1/07/13 → 30/06/16
Project: Research